|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2667-2674.
Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2004-03-0982.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
Georg Lenz,
Martin Dreyling,
Eva Schiegnitz,
Roswitha Forstpointner,
Hannes Wandt,
Mathias Freund,
Georg Hess,
Lorenz Truemper,
Volker Diehl,
Martin Kropff,
Michael Kneba,
Norbert Schmitz,
Bernd Metzner,
Markus Pfirrmann,
Michael Unterhalt, and
Wolfgang Hiddemann
From the Department of Internal Medicine III and the Department of Medical Informatics, Biometrics and Epidemiology, Ludwig-Maximilians University, Munich Grosshadern; Department of Hematology and Oncology, Klinikum Nord, Nuernberg; Department of Hematology and Oncology, University of Rostock; Department of Internal Medicine III, University Hospital Mainz; Department of Hematology and Oncology, Georg August University, Goettingen; Department of Internal Medicine I, University of Cologne; Department of Medicine, University of Muenster; Department of Internal Medicine II, University of Kiel; Department of Hematology, Allgemeines Krankenhaus St. Georg, Hamburg; and Department of Internal Medicine II, Klinikum Oldenburg, Germany.
Conventional chemotherapy has failed to substantially prolong survival for patients with advanced follicular lymphoma. To improve outcomes, the German Low-Grade Lymphoma Study Group (GLSG) initiated a randomized trial to compare the effect of potentially curative myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT) with interferon- (IFN-) maintenance therapy in first remission. Three hundred seven patients (younger than 60 years) with follicular lymphoma were recruited into the trial from 130 institutions. After 2 cycles of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) or mitoxantrone-chlorambucil-prednisone (MCP) induction chemotherapy, patients were randomly assigned to either the ASCT or the IFN- group. The respective therapy was started when patients achieved complete or partial remission after induction chemotherapy. Two hundred forty patients with follicular lymphoma are evaluable for the comparison of ASCT and IFN-. In patients who underwent ASCT, the 5-year progression-free survival (PFS) rate was 64.7%, and in the IFN- arm it was 33.3% (P < .0001). As expected, acute toxicity was higher in the ASCT group, but early mortality was below 2.5% in both study arms. In this randomized, multicenter trial, high-dose radiochemotherapy followed by ASCT significantly improved PFS compared with IFN- in patients with follicular lymphoma when applied as consolidation in first remission. Longer follow-up is necessary to determine the effect of ASCT on overall survival. (Blood. 2004;104:2667-2674)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Autologous transplantation for newly diagnosed follicular lymphoma: cure at last or not yet?
- Koen van Besien
Blood 2004 104: 2613-2614.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al.
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
Ann. Onc.,
April 1, 2009;
20(4):
722 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gyan, C. Foussard, P. Bertrand, P. Michenet, S. Le Gouill, C. Berthou, H. Maisonneuve, V. Delwail, R. Gressin, P. Quittet, et al.
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
Blood,
January 29, 2009;
113(5):
995 - 1001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum
Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow
J. Clin. Oncol.,
June 20, 2008;
26(18):
2927 - 2929.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Blood,
April 15, 2008;
111(8):
4004 - 4013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica,
November 1, 2007;
92(11):
1533 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol.,
June 20, 2007;
25(18):
2554 - 2559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al.
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Haematologica,
May 1, 2007;
92(5):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Witzens-Harig, C. Heilmann, M. Hensel, M. Kornacker, A. Benner, R. Haas, S. Fruehauf, and A. D. Ho
Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34+-Selected Peripheral Blood Progenitor Cells
Stem Cells,
January 1, 2007;
25(1):
228 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Nickenig, M Dreyling, E Hoster, W-D Ludwig, B Dorken, M Freund, C Huber, A Ganser, L Trumper, R Forstpointner, et al.
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group
Ann. Onc.,
January 1, 2007;
18(1):
136 - 142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. van Besien
Autologous transplantation for follicular lymphoma? Not too soon!
Blood,
October 15, 2006;
108(8):
2496 - 2497.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al.
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood,
October 15, 2006;
108(8):
2540 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Buske, E. Hoster, M. Dreyling, J. Hasford, M. Unterhalt, W. Hiddemann, and for the German Low Grade Lymphoma Study Group (GLS
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Blood,
September 1, 2006;
108(5):
1504 - 1508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al.
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
December 1, 2005;
106(12):
3725 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt
Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives
J. Clin. Oncol.,
September 10, 2005;
23(26):
6394 - 6399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, M. Unterhalt, and W. Hiddemann
In Reply:
J. Clin. Oncol.,
September 1, 2005;
23(25):
6264 - 6266.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Deconinck, C. Foussard, N. Milpied, P. Bertrand, P. Michenet, P. Cornillet-LeFebvre, M. Escoffre-Barbe, H. Maisonneuve, V. Delwail, R. Gressin, et al.
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS
Blood,
May 15, 2005;
105(10):
3817 - 3823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dreyling, G. Lenz, E. Hoster, A. Van Hoof, C. Gisselbrecht, R. Schmits, B. Metzner, L. Truemper, M. Reiser, H. Steinhauer, et al.
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
Blood,
April 1, 2005;
105(7):
2677 - 2684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
December 15, 2004;
22(24):
4926 - 4933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
